ライフサイエンスコーパス: hematological disorder

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 g the importance of PTN in the growth of any hematological disorder.

2 Polycythemia vera (PV) is a human clonal hematological disorder.

3 represents a curative treatment for various hematological disorders.

4 targeting the treatment of immunological and hematological disorders.

5 iously received a bone marrow transplant for hematological disorders.

6 owledge implicating the shelterin complex in hematological disorders.

7 ion (BMT) represents a cure for nonmalignant hematological disorders.

8 ant clinical traits and can indicate various hematological disorders.

9 could be extrapolated to MSC dysfunction in hematological disorders.

10 ation, variable chromosomal instability, and hematological disorders.

11 acute myeloid leukemia and treatment-related hematological disorders.

12 zebrafish as a genetic model to study human hematological disorders.

13 hroughput genetic screening for these common hematological disorders.

14 development of expansion strategies to treat hematological disorders.

15 ting, focusing on its potential for treating hematological disorders.

16 There were 30 cancers, 9 malignant hematological disorders, 14 chronic inflammatory disease

17 and increased incidence of anemia and other hematological disorders and malignancies.

18 data implicate hnRNP K in the development of hematological disorders and suggest hnRNP K acts as a tu

19 eme catabolism, is a key marker of liver and hematological disorders, and important cytoprotective pr

20 with sickle cell disease (SCD), an inherited hematological disorder associated with vascular inflamma

21 DNA, and anti-histone autoantibodies, severe hematological disorders, autoimmune glomerulonephritis,

22 be used effectively for in silico studies of hematological disorders based on first principles and pa

23 went laparoscopic splenectomy for a range of hematological disorders between November 1992 and Februa

24 om of MDS, a rare group of potentially fatal hematological disorders, but it has not previously been

25 For many nonmalignant hematological disorders, HLA-matched bone marrow transpl

26 Sickle cell disease (SCD) is a hematological disorder leading to blood vessel occlusion

27 regimen used in the context of nonmalignant hematological disorders leads to substantially higher ra

28 colitis (n=6), adrenal insufficiency (n=5), hematological disorders (n=3), dermatitis (n=1), and rhe

29 ts: IBD, n=67 (20.2%); RA, n=39 (11.8%); and hematological disorders, n=13 (3.9%).

30 ree patients all had histories of underlying hematological disorders, presented with fever, and recov

31 Most nonmalignant hematological disorders require transfusion support prio

32 However, in many hematological disorders the spectrin network and lipid b

33 tem cells, describe progress toward modeling hematological disorders using iPS cells, and illustrate

34 rk toward the possible treatment of numerous hematological disorders using iPSC technologies.

35 Patients with various hematological disorders who underwent splenectomy betwee

36 Acute myelogenous leukemia is a hematological disorder with a predilection for gingival

37 anemia (SCA) is a well characterized severe hematological disorder with substantial morbidity and ea

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。